BML Capital Management LLC Takes Position in Palvella Therapeutics (NASDAQ:PVLA)

BML Capital Management LLC purchased a new stake in shares of Palvella Therapeutics (NASDAQ:PVLA) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 42,130 shares of the company’s stock, valued at approximately $506,000. Palvella Therapeutics comprises approximately 0.3% of BML Capital Management LLC’s portfolio, making the stock its 18th largest holding.

Palvella Therapeutics Trading Up 7.2 %

PVLA opened at $23.94 on Friday. The firm’s fifty day simple moving average is $15.69. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $24.00. The stock has a market cap of $268.63 million, a PE ratio of -1.98 and a beta of 0.54.

Analyst Ratings Changes

PVLA has been the topic of several recent analyst reports. TD Cowen initiated coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They set a “buy” rating and a $44.00 price objective on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $39.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Cantor Fitzgerald started coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an “overweight” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $38.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, February 11th.

Insiders Place Their Bets

In related news, Director George M. Jenkins purchased 4,000 shares of Palvella Therapeutics stock in a transaction dated Wednesday, December 18th. The stock was purchased at an average cost of $12.93 per share, with a total value of $51,720.00. Following the transaction, the director now owns 180,671 shares in the company, valued at approximately $2,336,076.03. The trade was a 2.26 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.39% of the company’s stock.

Palvella Therapeutics Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.